Last reviewed · How we verify
Cobefrin (nordefrin)
Cobefrin (generic name: nordefrin) is a nordefrin drug. It is currently in unknown development.
Cobefrin works by stimulating the sympathetic nervous system to increase the levels of certain neurotransmitters.
Cobefrin, also known as nordefrin, is a small molecule drug in the nordefrin class. It is a sympathomimetic agent that works by stimulating the sympathetic nervous system. However, due to the lack of available information, its target, approved indications, and commercial status are unknown. Further research is needed to determine its efficacy and safety profile. As a result, it is not possible to provide a comprehensive summary of Cobefrin at this time.
At a glance
| Generic name | nordefrin |
|---|---|
| Drug class | nordefrin |
| Target | Adrenergic receptor alpha-2 |
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your body's 'fight or flight' response, where your heart beats faster and your senses become more alert. Cobefrin helps trigger this response by increasing the levels of certain chemicals, called neurotransmitters, that send signals to your brain and body. This can help increase blood pressure and heart rate, among other effects.
Approved indications
Common side effects
Key clinical trials
- Healing Process and Blood Sugar Level Following Local Anesthetic Infiltration With and Without Vasoconstrictor (NA)
- Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock (NA)
- Assessment of Clinical & Radiographic Efficiency of Manual & Pediatric Rotary Systems in Primary Root Canal Preparation (NA)
- Insertion of Immediate Cortical Satellite Implants With Immediate Loading (NA)
- Anesthetic Efficacy of %4Alexadricaine Versus %2 Mepicaine-L in Children (PHASE3)
- Effect of Sodium Alendronate on the Final Implant Stability. (EARLY_PHASE1)
- Effect of Magnesium Sulphate Added to Mepivacaine Hydrochloride on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial. (NA)
- Pain Assessment During Mandibular Nerve Block Injection With the Aid of Dental Vibe Tool in Pediatric Dental Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cobefrin CI brief — competitive landscape report
- Cobefrin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Cobefrin
What is Cobefrin?
How does Cobefrin work?
What is the generic name of Cobefrin?
What drug class is Cobefrin in?
What development phase is Cobefrin in?
What does Cobefrin target?
Related
- Drug class: All nordefrin drugs
- Target: All drugs targeting Adrenergic receptor alpha-2
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing